Merck KGaA to expand inorganic salts capacity 50%

By Gareth Macdonald

- Last updated on GMT

Related tags: Active ingredient, Pharmacology, Merck kgaa

Merck KGaA has begun work on a new inorganic salts plant in Darmstadt, Germany, citing growing demand as the main motivation for the €30m ($42m) investment.

The facility, due to become operational in mid-2011, will employ crystallisation to produce chemicals used in active pharmaceutical ingredients (APIs), drug excipients and biopharmaceutical reagents on a contractual basis.

Company spokesman Gangolf Schrimpf said the plant, which will also supply inorganic salts to customers in the food industry, is part of an expansion of the German drug and chemical firm’s laboratory and life science solutions businesses.

Dr Schrimpf told in-PharmaTechnologist that: “[Merck] decided to scale up its production capacities for inorganic salts to respond to the growing global demand,​” and added that it will position the division as a significant player in the industry.

He also predicted that Merck’s ability to control the entire inorganic salt manufacturing process will be highly valued by pharmaceutical industry clients for whom drug ingredient safety and quality are paramount.

The new inorganics facility is part of a wider expansion of Merck’s performance and life science chemicals division that began with the construction of a €47m materials research centre at the Darmstadt site in 2008.

In a press statement, Klaus Bischoff, head of life science division said that: “We want to grow along with our customers.

“This expansion of capacity and modernization is our response to the growing global demand for and high requirements placed on quality and product safety for final pharmaceutical and biopharmaceutical formulations.”

Related news

Show more

Related products

show more

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...


NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

Related suppliers

Follow us


View more